Screening children at risk of developing inherited endocrine neoplasia syndromes (Q33836070)

29 July 2017

1 reference

title

Screening children at risk of developing inherited endocrine neoplasia syndromes (English)

1 reference

29 July 2017

6

Besser GM

1 reference

29 July 2017

5

Grossman AB

1 reference

29 July 2017

8

Savage MO

1 reference

29 July 2017

Johnston LB

1

1 reference

29 July 2017

Chew SL

2

1 reference

29 July 2017

Trainer PJ

3

1 reference

29 July 2017

Reznek R

4

1 reference

29 July 2017

Monson JP

7

1 reference

29 July 2017

publication date

1 February 2000

1 reference

29 July 2017

published in

Clinical Endocrinology

1 reference

29 July 2017

volume

52

1 reference

29 July 2017

issue

2

1 reference

29 July 2017

page(s)

127-136

1 reference

Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

Characterization of mutations in patients with multiple endocrine neoplasia type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

Chromogranin A as tumor marker in medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

Positional cloning of the gene for multiple endocrine neoplasia-type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

Management of patients and subjects at risk for multiple endocrine neoplasia type 1: MEN 1. GENEM 1. Groupe d'Etude des Néoplasies Endocriniennes Multiples de type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

von Hippel-Lindau disease: genetic, clinical, and imaging features

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

The natural history of renal lesions in von Hippel-Lindau disease: a serial CT study in 28 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

Inhibition of Transcription Elongation by the VHL Tumor Suppressor Protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

Von Hippel-Lindau disease: clinical and pathological manifestations in nine families with 50 affected members

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

Chromogranin A in familial pheochromocytoma: diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating two-compartment distribution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

RET protooncogene mutational analysis in multiple endocrine neoplasia syndrome type 2B: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

Binding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

Identification of the von Hippel-Lindau disease tumor suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

A genetic register for von Hippel-Lindau disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

LINDAU'S DISEASE. REVIEW OF THE LITERATURE AND STUDY OF A LARGE KINDRED.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

Pancreatic polypeptide is a useful plasma marker for radiographically evident pancreatic islet cell tumors in patients with multiple endocrine neoplasia type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

Central nervous system lesions in von Hippel-Lindau syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

Hemangioblastomas of the central nervous system. A 10-year study with special reference to von Hippel-Lindau syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

The use of venous catheterization in the diagnosis and localization of bilateral phaeochromocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

Plasma and 24 h-urinary catecholamine concentrations in normal and patient populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2000.00956.X

10.1046/J.1365-2265.2000.00956.X

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference